Monitoring Salivary Gland Injury in Nasopharyngeal Carcinoma Patients After Radiotherapy Using Multi-Modal Radiomics

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorHainan Medical College

About this trial

This prospective observational study aims to evaluate the role of intravoxel incoherent motion (IVIM) imaging and magnetic resonance fingerprinting (MRF) techniques in monitoring salivary gland injury in nasopharyngeal carcinoma (NPC) patients undergoing radiotherapy. The study will recruit patients diagnosed with NPC who are receiving standard radiotherapy, and quantitative imaging data will be collected using IVIM and MRF techniques at multiple time points, including pre-treatment, during radiotherapy, and post-treatment. The primary objective is to analyze changes in salivary gland structure and function and to identify early imaging biomarkers indicative of radiation-induced injury. The findings are expected to provide new insights into the dynamic progression of salivary gland damage, establish predictive models for the risk of xerostomia, and guide the development of personalized therapeutic strategies to mitigate long-term complications.

Eligibility criteria

Qualifiers

Histologically or cytologically confirmed diagnosis of nasopharyngeal carcinoma.

Scheduled to undergo radiotherapy as part of standard treatment.

Aged 18 years or older.

No contraindications to MRI scans (e.g., no implanted metallic devices).

Disqualifiers

Contraindications to MRI, such as metallic implants or claustrophobia.

Severe comorbid conditions, including significant renal or hepatic dysfunction.

Concurrent participation in another interventional clinical trial.

Pregnant or breastfeeding.

Trial design

Treatments tested in this trial

  • IVIM Imaging MRF Imaging

Treatment groups

45 Participants
are divided into 1 treatment group

Locations

This trial has no locations

Sponsors and collaborators

Hainan Medical College

Lead sponsor

Hainan People's Hospital

Sponsor institution